Key points are not available for this paper at this time.
Nivolumab monotherapy was better tolerated than nivolumab + ipilimumab; the tolerability of the combination was influenced by ipilimumab dose. These safety and exploratory findings merit further investigation of immunotherapies in glioblastoma.
Building similarity graph...
Analyzing shared references across papers
Loading...
Antonio Omuro
Gordana Vlahovic
Michael Lim
Neuro-Oncology
Harvard University
Yale University
University of California, Los Angeles
Building similarity graph...
Analyzing shared references across papers
Loading...
Omuro et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69def9dc57c7c8340a55984d — DOI: https://doi.org/10.1093/neuonc/nox208